Canurta Journal

In August 2025, Canurta launched the Satoshi Trials to integrate Bitcoin into its treasury model, achieved a key blood-brain barrier milestone for CNR-401, signed a public market LOI with PharmaDrug, and CEO Akeem Gardner spoke on innovation at CanadianSME and the Black Blockchain Summit.

In July 2025, Canurta signed an LOI with PharmaDrug Inc., joined Next Sequence’s AI x Bio Accelerator, discovered new bioactive flavonoids, and shared promising data on glioblastoma and ALS models—all while preparing for C2MP Final Pitch Day.

In June 2025, Canurta signed a Letter of Intent to merge with extractX Ltd., advanced CNR-401 through preclinical development, unveiled new data at ENCALS, and launched the alpha version of its AI-powered Polykye™ platform.

In May 2025, Canurta advanced preclinical studies for CNR-401, showcased CNR-301 at MedCity INVEST, launched an open-source platform via the Base Batch Buildathon, and graduated from the CDL Neuro 2024/25 cohort.

In April 2025, Canurta Therapeutics was named a finalist for MedCity INVEST, made breakthroughs in biosynthesis and AI drug discovery, and celebrated CEO Akeem Gardner's recognition as one of Canada's Top 20 Under 40 in Life Sciences.

In February 2025, Canurta Therapeutics achieved key regulatory milestones with Pre-IND and Orphan Drug submissions for CNR-401. We also expanded preclinical studies with WSU, enhanced AI-driven quality control, and gained traction in the C2MP U.S. expansion program.

In February 2025, Canurta Therapeutics achieved key regulatory milestones with Pre-IND and Orphan Drug submissions for CNR-401. We also expanded preclinical studies with WSU, enhanced AI-driven quality control, and gained traction in the C2MP U.S. expansion program.

In January 2025, Canurta joined the prestigious Canada-Chicago Mentoring Program, connected with industry leaders at the J.P. Morgan Healthcare Conference, shared research at the SUNY Cannabis Conference, and advanced its Pre-IND milestones with the FDA.

This month, Canurta presented groundbreaking ALS research at the ALS/MND Symposium, shared insights with Lambton College, appeared on The Global Marketing Show, and continued scientific advances in biosynthesis and molecular fingerprinting.

Canurta Therapeutics presents new research at the ALS/MND Symposium, explores next-gen therapeutics at CB1 & CB2 Summit, joins NVIDIA Inception and Canada-Chicago Mentoring Program, and continues breakthroughs in bioinformatics and ALS biomarker discovery.

CEO Akeem Gardner reflects on Canurta’s momentum this fall, from securing $2.25M in commitments to pitching at ACT Canada, publishing new findings on Cannabistilbene I, joining the CDL program for arthritis, and advancing biomarker research for ALS.

CEO Akeem Gardner shares positive biotech market outlook and Canurta’s latest milestones, including early Pre-Seed traction, showcasing at CHFA, investor engagement at RESI Boston, and continued advances in flavonoid drug development and ALS biomarker research.

In his latest letter, CEO Akeem Gardner addresses market challenges, outlines Canurta’s strategic growth initiatives, and announces the launch of a $5M Pre-Seed round. Plus, insights from CannMedTM 2024 and a new flavonoid compound advancing to anticancer testing.

This July, Canurta achieved a major milestone with the granting of its first US patent for a novel polyphenol extraction process. The team also visited key partners in Québec to advance large-scale botanical extraction methods and continued progressing its ALS research with cutting-edge bioinformatics.

June was a milestone month for Canurta, with the successful launch of FutureBotanica 2024, key presentations at Mars Impact Health and Collision, and active sponsorship at the CSPS Symposium. We also advanced ALS research through community events like the Pull to End ALS and the Ice Bucket Challenge, while progressing R&D on solid lipid nanoparticle delivery.

In May, Canurta presented key research findings at the ALS Drug Development Summit and CannMed 2024, reinforcing its commitment to ALS and neurodegenerative disease innovation. Additional highlights include participation at EFFERVESCENCE, a feature in BIOTECanada’s Insights magazine, preparations for the 2024 ALS Pull, and new educational initiatives from Dr. Ethan Russo.

Canurta announced its flagship event, FutureBotanica 2024, to spotlight innovation in botanical drug development. The company also participated in 1871’s Cannabis Innovation Lab, Bloom Burton’s Healthcare Investor Conference, and sponsored the ALS Canada Research Forum. April milestones included progress on nanoparticle formulations, new extraction technology, and a PCA fingerprinting pipeline for quality control.

March marked a month of significant momentum for Canurta, including conditional approval for its Grimsby research facility, strategic MOUs with Algoma University and BasgenBIO, and a new U.S. provisional patent supported by IPON. Additional highlights include upcoming speaking engagements, FilingFlow’s Phase 2 rollout, and new progress in ALS biomarker discovery.

In January, Canurta was selected to speak at CannMed 2024 on new treatments for neurological disorders, joined the Cannabis Innovation Lab, and participated in Arab Health 2024 in Dubai and JP Morgan Healthcare Week. Key R&D milestones included positive ALS model results and acquisition of the Answer ALS dataset to support targeted drug development.

In December, Canurta participated in the 34th International Symposium on ALS/MND in Switzerland and shared key insights from the Global Healthspan Summit in Riyadh. The company continued to progress its ALS formulation, launched branded merchandise, and prepared for its 2024 clinical operations.